Literature DB >> 14605060

An analysis of the association between preoperative renal dysfunction and outcome in cardiac surgery: estimated creatinine clearance or plasma creatinine level as measures of renal function.

Feng Wang1, Jean-Yves Dupuis, Howard Nathan, Kathryn Williams.   

Abstract

STUDY
OBJECTIVES: Preoperative renal dysfunction is a risk factor for adverse events in cardiac surgery. This study compared creatinine clearance (ClCr), estimated from the Cockroft and Gault formula, and plasma creatinine level as predictors of outcome after cardiac surgery.
DESIGN: Prospective, observational.
SETTING: University hospital. PATIENTS: A total of 6,364 cardiac surgical patients.
METHODS: The measured outcomes were postoperative renal failure requiring dialysis, and mortality and major morbidity. For each outcome, two multivariable risk models were developed, using either estimated ClCr as a measure of renal function, or plasma creatinine level. Risk-adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated for each outcome. Discrimination was compared using receiver operating characteristic (ROC) curves.
RESULTS: For each 10 mL/min/1.73 m(2) decrement of estimated ClCr, the ORs for renal failure requiring dialysis, mortality, and major morbidity in the whole population were 1.52 (95% CI, 1.35 to 1.67), 1.27 (95% CI, 1.19 to 1.35), and 1.18 (95% CI, 1.14 to 1.21), respectively; for each 0.2 mg/dL increment of plasma creatinine, ORs were 1.20 (95% CI, 1.15 to 1.26), 1.08 (95% CI, 1.04 to 1.13), and 1.12 (95% CI, 1.09 to 1.15), respectively. The areas under the ROC curves for prediction of renal failure requiring dialysis were 0.83 with both risk models. For prediction of mortality and major morbidity, areas under the ROC curves were 0.83 and 0.72, respectively, with the models using estimated ClCr, and 0.74 and 0.65, respectively, with the models using plasma creatinine level (p < 0.001 vs estimated ClCr for both outcomes). In patients with normal plasma creatinine levels (n = 4,603), estimated ClCr remained a significant predictor of each outcome with similar ORs, but plasma creatinine level was not a predictor of any outcome.
CONCLUSION: The risk-adjusted association between preoperative renal dysfunction and adverse events after cardiac surgery is stronger with estimated ClCr than with plasma creatinine level, particularly in patients with normal plasma creatinine levels. The routine preoperative estimation of ClCr may improve the identification of higher-risk cardiac surgical patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605060     DOI: 10.1378/chest.124.5.1852

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Impact of occult renal impairment on early and late outcomes following coronary artery bypass grafting.

Authors:  Akira Marui; Hitoshi Okabayashi; Tatsuhiko Komiya; Shiro Tanaka; Yutaka Furukawa; Toru Kita; Takeshi Kimura; Ryuzo Sakata
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-06-21

2.  Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools.

Authors:  Danny Lascano; Jamie S Pak; Max Kates; Julia B Finkelstein; Mark Silva; Elizabeth Hagen; Arindam RoyChoudhury; Trinity J Bivalacqua; G Joel DeCastro; Mitchell C Benson; James M McKiernan
Journal:  Urol Oncol       Date:  2015-07-09       Impact factor: 3.498

3.  Effect of preoperative renal insufficiency on postoperative outcomes after pancreatic resection: a single institution experience of 1,061 consecutive patients.

Authors:  Malcolm H Squires; Vishes V Mehta; Sarah B Fisher; Neha L Lad; David A Kooby; Juan M Sarmiento; Kenneth Cardona; Maria C Russell; Charles A Staley; Shishir K Maithel
Journal:  J Am Coll Surg       Date:  2013-11-07       Impact factor: 6.113

4.  Impact of pretreatment asymptomatic renal dysfunction on clinical course after esophagectomy.

Authors:  Yuki Kirihataya; Kohei Wakatsuki; Sohei Matsumoto; Hiroshi Nakade; Tomohiro Kunishige; Shintaro Miyao; Masayuki Sho
Journal:  Surg Today       Date:  2020-08-29       Impact factor: 2.549

5.  Model for end-stage liver disease predicts mortality for tricuspid valve surgery.

Authors:  Gorav Ailawadi; Damien J Lapar; Brian R Swenson; Suzanne A Siefert; Christine Lau; John A Kern; Benjamin B Peeler; Keith E Littlewood; Irving L Kron
Journal:  Ann Thorac Surg       Date:  2009-05       Impact factor: 4.330

6.  Cerebrovascular CO2 reactivity during isoflurane-nitrous oxide anesthesia in patients with chronic renal failure.

Authors:  Kazuyoshi Ishida; Masato Uchida; Kohji Utada; Atsuo Yamashita; Satoshi Yamashita; Shiro Fukuda; Mishiya Matsumoto; Takefumi Sakabe
Journal:  J Anesth       Date:  2017-11-04       Impact factor: 2.078

Review 7.  Interventions for protecting renal function in the perioperative period.

Authors:  Mathew Zacharias; Mohan Mugawar; G Peter Herbison; Robert J Walker; Karen Hovhannisyan; Pal Sivalingam; Niamh P Conlon
Journal:  Cochrane Database Syst Rev       Date:  2013-09-11

8.  The simplified modification of diet in renal disease equation as a predictor of renal function after coronary artery bypass graft surgery.

Authors:  M J Swart; A M Bekker; J J Malan; A Meiring; Z Swart; G Joubert
Journal:  Cardiovasc J Afr       Date:  2010 Jan-Feb       Impact factor: 1.167

9.  Potentially modifiable risk factors for acute kidney injury after surgery on the thoracic aorta: a propensity score matched case-control study.

Authors:  Won Ho Kim; Mi Hye Park; Hyo-Jin Kim; Hyun-Young Lim; Haeng Seon Shim; Ju-Tae Sohn; Chung Su Kim; Sangmin M Lee
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

10.  The predictive value of five glomerular filtration rate formulas for long-term mortality in patients undergoing coronary artery bypass grafting.

Authors:  Eilon Ram; Yael Peled; Ehud Karni; Efrat Mazor Dray; Hillit Cohen; Ehud Raanani; Leonid Sternik
Journal:  J Card Surg       Date:  2022-06-15       Impact factor: 1.778

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.